Latest News and Press Releases
Want to stay updated on the latest news?
-
Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Treatment Market Size, Share and Trends Analysis Report by Type (Evaporative, Aqueous Deficient), Drug, Product, Dosage Form, Sales...
-
Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Ophthalmic Drugs...
-
Rockville , Jan. 04, 2024 (GLOBE NEWSWIRE) -- The global dry eye syndrome treatment market is projected to be worth US$ 4,027.2 million in 2024. Projected economic growth through 2034 is expected to...
-
New York, April 20, 2023 (GLOBE NEWSWIRE) -- The Dry Eye Syndrome Treatment Market is expected to generate US$ 4.8 billion in revenue globally in 2022, and is projected to grow at a CAGR of 7.1% to...
-
Dublin, April 17, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Treatment - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Indication, By Product Type, By...
-
DUBAI, United Arab Emirates, March 02, 2023 (GLOBE NEWSWIRE) -- The global dry eye syndrome treatment market is anticipated to exceed a value of US$ 8.84 billion by 2032, with sales growing at a...
-
Burlingame, Feb. 10, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global dry eye syndrome treatment market is estimated to be valued at US$ 7,245.3 million in 2022 and is...
-
SEATTLE, May 27, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global eye health supplement market is estimated to be valued at US$ 2,258.8 million in 2020 and is expected to...
-
VALLEY COTTAGE, N.Y. , June 07, 2018 (GLOBE NEWSWIRE) -- Common forms of artificial tears are known for being quick-fix remedies to dry eye syndrome. Drops of artificial tears with CMC and HPMC...
-
Valley Cottage, New York, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Some of the key players in the global market for dry eye syndrome treatment include names such as Nicox, Candorvision, Novartis, Allergan...